INTRODUCING 250+ TOP BIOPHARMA SPEAKERS

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Research Laboratories (Merck Sharp & Dohme). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice...

Katherine High, President And Head, Research And Development, Spark Therapeutics

Dr. Kathy High, an accomplished hematologist with a longstanding interest in gene therapy for genetic disease, began her career studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside...

Andrew Obenshain, Head Of Europe, Bluebird Bio

Andrew Obenshain is Head of Europe at bluebird bio, a biotech company focused on developing potentially transformative cell & gene therapies for severe genetic and rare diseases.Before taking up this role in 2016, he was at Shire in Paris, France where he was the general manager of France and...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

Shinya Yamanaka, Director And Professor, Center For Ips Cell Research And Application (Cira), Kyoto University

Professor Shinya Yamanaka is most recognized for his discovery of induced pluripotent stem cells (iPSC), which are differentiated cells that have been reprogrammed to the pluripotent state. He is Director of the Center for iPS Cell Research and Application (CiRA), which was founded in 2008 in...

Dr James Miskin, Chief Technical Officer, Oxford Biomedica

Dr James Miskin is Chief Technical Officer at Oxford BioMedica Plc. James obtained his Ph.D in bacterial molecular biology in 1995 from the University of Leeds, UK. He then worked for over five years as a post‐doctoral research scientist at the UK government‐funded Institute for Animal...

Frederic Chereau, Chief Executive Officer, LogicBio Therapeutics

Frederic Chereau currently serves as President and Chief Executive Officer of LogicBio Therapeutics. From 2014 to 2015, Mr. Chereau was President and Chief Operating Officer of aTyr Pharma (LIFE). During his tenure, the company advanced multiple programs to clinical stage and successfully completed ...

Lothar Germeroth is Senior Vice President at Juno Inc. and Managing Director at Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of management experience in biotechnology. Dr. Germeroth served as the CEO at IBA...

Derek is a 15-year veteran of the genome editing industry. As a protein engineer, he was an early developer of zinc finger technology and has spent most of his research career designing proteins for genome editing applications. He has a B.A. in biology from the University of Colorado at Boulder and ...

Michael Leek, Chief Executive Officer, TC BioPharm

Michael has 27 years’ experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy ...

Lior Raviv, Vice President Of Development, Pluristem

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development in charge on process & technology development and manufacturing sciences. Prior to that Mr. Raviv served as Projects manager & Product development Team leader at Pluristem in charge of new technologies ...

Edward Rebar, has served as Senior Vice President and Chief Technology Officer since July 2018. Dr. Rebar joined Sangamo in 1998, and over the last 20 years has led the development of the Company's zinc finger protein technology platform. He has authored over 60 publications relating to the...

Dominic Schmidt, Partner, Syncona Investment Management Ltd

Dominic is a Partner of Syncona. Prior to joining Syncona, he worked in the life sciences team of strategy consultancy L.E.K. Consulting. Dominic received his PhD from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom ...

Jean-Pierre Latere, Chief Operating Officer, Celyad

Jean-Pierre (COO) joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management, clinical operations and regulatory affairs. He started his career as a Research Associate at the Michigan State University in the...

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on...

Jacqueline joined Cell and Gene Therapy Catapult as Director of Regulatory Affairs and has since been promoted to Chief Clinical Officer.Prior to this Jacqueline worked at the Scottish National Blood Transfusion Service in a number of senior regulatory and quality positions, the responsibility for...

I am a pediatric hematologic oncologist and Chief of the Pediatric Stem Cell Transplantation and Cellular Therapies Service. I specialize in bone marrow and cord blood transplantation to treat blood diseases in children and young adults. I have particular expertise in treating rare diseases, such...

Armando Cuesta Díaz, Partner, Ilana Capital

Fund manager at Abante Biotech Fund. MD with more than 10 years of experience in the life-sciences industry. Experience in conducting laboratory and clinical research at institutions such as Icahn School of Medicine at Mount Sinai and Albert Einstein College of Medicine in New York City. Member of...

Prior to joining Histogenics, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior...

David Pauza, Chief Science Officer, American Gene Technologies International Inc.

C. David Pauza, PhD is Chief Science Officer for American Gene Technologies and Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university’s prestigious Institute of Human Virology and Co-Leader of the...

Beth Shaz, Chief Medical Officer, New York Blood Center

Beth Shaz, MD, is chief medical officer, senior vice president of Medical Programs and Services and co-director of the Lindsey F. Kimball Research Institute at New York Blood Center (NYBC). She is responsible for all medical activities, including hemophilia services, transfusion services, cellular ...

Jonathan trained as a doctor at Dundee University, before following a career as a histopathologist at Yeovil District Hospital, where he was instrumental in developing its research capabilities. In 2003 he became Medical Director for the Trust, before moving on to University Hospitals Bristol –...

Marcos Valadares, Co-Founder, Pluricell

Marcos Valadares is a brazilian entrepreneur with a major in biology and a doctorate in human genetics and stem cell biology from the University of São Paulo (USP) and MBA from Instituto Butanta. I have co-founded two companies including a PluriCell Biotech which develops cell based regenerative...

Miguel Forte, Chief Executive Officer, Zelluna Immunotherapy

Currently the CEO of Zelluna Immunotherapy and visiting Professor at the Lisbon and Aveiro Universities in Portugal. Currently also serving as Chief Commercialization Officer and Chair of the Commercialization Committee of the International Society of Cell and Gene Therapy (ISCT). From February...

Edward Hodgkin, Partner, Syncona Partners

Edward Hodgkin is a Partner of Syncona Partners LLP and a Non-Executive Director of Autolus Ltd, where he served as CEO from the company’s inception in September 2014 until March 2016. Autolus is developing a series of next-generation engineered T-cell products for treatment of haematological and...

Hans Keirstead, Chief Executive Officer, AiVita Biomedical

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

David Mazzo, Chief Executive Officer, Caladrius Biosciences

David J. Mazzo was appointed as Caladrius' Chief Executive Officer and as a member of our Board on January 5, 2015. In addition, Dr. Mazzo was appointed as President of the Company in March 2017. Dr. Mazzo brings to the Company over 30 years of experience in the pharmaceutical industry. Prior...

David Morrow, Program Manager, EATRIS

David Morrow is Programme Manager Translational Medicine & Drug Development at EATRIS.David received a BSc (Hons) in Molecular Biology from University College Dublin in 2001 and a PhD in Vascular Biology from Dublin City University in 2006. This was followed by an American Heart Association...

Mark Sawicki, Chief Commercial Officer, Cryoport Inc

Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport, which provides end-to-end cold chain logistics solutions to the life sciences industry. Sawicki, who has more than 15 years’ experience in the pharmaceutical and biotechnology industries, holds a bachelor’s in biochemistry from the State...

Bill Douglass│Gotham Communications <Claudia Mitchell is the co-founder and COO of Universal Cells Inc., a Seattle-based biotech company. Claudia was the CEO of Universal Cells until February 2018, when the company was acquired by Astellas Pharma Inc. Claudia has previously co-founded Halo-Bio...

As an attending physician in the Cancer Center, Director of the Cancer Immunotherapy Program, Director of Translational Research of the Center for Childhood Cancer Research, and the Director of the Stem Cell Laboratory, I take on many roles here at CHOP. But in each of them, I’m a pediatric...

Takashi Kei Kishimoto, Chief Science Officer, Selecta Biosciences Inc

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led...

The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.